23 February 2018 - Pfizer today announced that the CHMP of the EMA has recommended against expanding use of Sutent (sunitinib maleate) to include the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma following nephrectomy. 

The CHMP’s recommendation is not binding but will now be taken into consideration by the European Commission. There is currently no approved adjuvant treatment option available for patients with non-metastatic renal cell carcinoma at high risk for recurrence in the European Union.

In the U.S., Sutent is approved for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

Read Pfizer press release